Literature DB >> 30684505

The prevalence of retinopathy in patients with type 1 diabetes treated with education-based intensified insulin therapy and its association with parameters of glucose control.

Katja Hatz1, Anna Elisabeth Minder2, Roger Lehmann3, Tilman Drescher4, Bianca Gerendas5, Ursula Schmidt-Erfurth5, Alexandra Kaider6, Christian Pruente7, Henryk Zulewski8.   

Abstract

AIM: Prevalence of retinopathy (DR) in patients with type 1 diabetes treated with education-based intensified insulin therapy (EBIIT) and its association with parameters of glucose control.
METHODS: 151 patients with mean diabetes duration of 14.3 years [SD ± 5.8]) were analyzed. Eyes were examined using standardized 7 field ETDRS (Early Treatment Diabetic Retinopathy Study) settings and images analyzed by a professional external reading center. The glucose exposure over time was defined as HbA1c years, i.e. the sum of the differences between annual mean HbA1c (in %) minus the ideal HbA1c of 6.0% (42 mmol/mol) for each diabetes year (e.g. HbA1c of 8% (64 mmol/mol) over 6 years gives an excess HbA1c of 2.0% (22 for mmol/mol) for 6 years, resulting in 12 HbA1c years (or 131 for mmol/mol)).
RESULTS: The median (interquartile range) of individual mean HbA1c was 7.3% (6.8-7.8) [56 mmol/mol (51-62)]. and the median HbA1c years was 16.8 (9.1-29.1) [183 mmol/mol (99-319)]. No evidence for DR was found in 59 patients (39%), stage 1 DR in 43 (28.5%), stage 2 in 41 (27.2%), stage 3 in 7 (4.6%) and proliferative DR stage 4 in 1 patient. The best correlation between severity of DR and diabetes control measures was found for HbA1c years (Pearson r = 0.41, p < 0.001).
CONCLUSIONS: In type 1 diabetes EBIIT is associated with good diabetes control and a low prevalence of DR. The cumulative glucose exposure over time given as HbA1c years is the best predictor for development of DR. ClinicalTrials.gov Identifier: NCT02307110.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Education based insulin therapy; Retinopathy prevalence

Mesh:

Substances:

Year:  2019        PMID: 30684505     DOI: 10.1016/j.diabres.2019.01.016

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  2 in total

1.  Therapeutic effects of different doses of prebiotic (isolated from Saccharomyces cerevisiae) in comparison to n-3 supplement on glycemic control, lipid profiles and immunological response in diabetic rats.

Authors:  Janina de Sales Guilarducci; Breno Augusto Ribeiro Marcelino; Isaac Filipe Moreira Konig; Tamira Maria Orlando; Mary Suzan Varaschin; Luciano José Pereira
Journal:  Diabetol Metab Syndr       Date:  2020-08-10       Impact factor: 3.320

2.  Ganglion cell layer thickening in well-controlled patients with type 1 diabetes: an early sign for diabetic retinopathy?

Authors:  Bianca S Gerendas; Katja Hatz; Alexandra Kaider; Henryk Zulewski; Roger Lehmann; Alessio Montuoro; Ursula Schmidt-Erfurth; Christian Pruente
Journal:  Acta Ophthalmol       Date:  2019-10-25       Impact factor: 3.761

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.